A case of primary hepatic lymphoma and review of the literature

Dragan Mašulović¹,², Aleksandar Filipović¹,², Miloš Zakošek¹, Dušan Bulatović¹, Milica Stojadinović¹

¹Clinical center of Serbia, Center for radiology and MR imaging, Belgrade, Serbia; ²University of Belgrade, Faculty of Medicine, Belgrade, Serbia

Received: March 10, 2019  
Revised: September 4, 2020  
Accepted: September 5, 2020  
Online First: September 11, 2020  
DOI: https://doi.org/10.2298/SARH200310069M

Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the Serbian Archives of Medicine. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication. Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author’s last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017. When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

Correspondence to: 
Dragan MAŠULOVIĆ  
Clinical center of Serbia,  
Pasterova 2, 11000 Belgarde, Serbia  
Email: draganmasulovic@yahoo.com
A case of primary hepatic lymphoma and review of the literature

SUMMARY
Introduction Primary hepatic lymphoma (PHL) is a rare disease and represents a lymphoproliferative disorder confined to the liver parenchyma. This condition is difficult to distinguish from other liver diseases. Histopathology is essential and confirms the diagnosis. Treatment options for PHL include surgery, chemotherapy, radiation or combinations of these modalities. The objective of this report is to present a case of primary hepatic lymphoma and to discuss disease features and treatment options in order to facilitate diagnostics and therapy.

Case Outline A 72-year-old female was presented with abdominal pain, nausea, weight loss and fatigue. Computed tomography (CT) revealed hypoattenuating solitary lesion in liver segment VIII. Detected liver lesion showed elevated 18F-FDG uptake on PET-CT examination. Extraphagic disease was not detected. The tumor board opted for surgery and atypical resection of liver segments VII and VIII was performed. Pathohistological examination of the resected tumor demonstrated liver infiltration with non-Hodgkin’s lymphoma (NHL), diffuse large B-cell type (DLBCL). Postoperative recovery was complicated with fluid collections in the right subhepatic space successfully managed by percutaneous drainage. Subsequently, patient was treated with chemotherapy and attained a complete remission documented by negative computed tomography.

Conclusion PHL can easily be misdiagnosed as another more frequent primary liver tumor due to its non-specific clinical manifestations, laboratory and imaging findings and therefore should be considered in the differential diagnosis of a hepatic lesion.

Key words: chemotherapy, drainage, liver, operative, tumor.

INTRODUCTION
Primary hepatic lymphoma (PHL) is a lymphoproliferative disorder confined to the liver without any evidence of spleen, lymph nodes, bone marrow, or other lymphoid structures involvement [1]. PHL is a rare disease and accounts for 0.4% of all extranodal lymphoma and 0.016% of all non-Hodgkin’s lymphoma (NHL) [2]. PHL of diffuse large B-cell lymphoma (PHL-DLBCL) is more infrequent [3].

PHL typically occurs in middle-aged men, and usually the presenting symptoms, blood investigations and imaging findings are nonspecific [1]. This condition is difficult to
distinguish from primary liver cancer, liver metastases, granulomatous pseudotumor, and other liver diseases therefore it is easily misdiagnosed [3]. Histopathology is mandatory and confirms the diagnosis. A patient with PHL is presented. A better understanding of the disease will facilitate diagnostics and therapy. We contribute our experience to the pool of data. Written informed consent was obtained from the patient for publication of this case report and accompanying images.

CASE REPORT

A 72-year-old female presented with abdominal pain, nausea, weight loss, fatigue and was examined in the emergency room. Abdominal ultrasound revealed an irregular heterogeneous, predominantly hypoechoic, 42x45mm lesion in liver segments VII and VIII. Computed tomography (CT) revealed 58x49x54mm hypoattenuating lesion, adjacent to the right hepatic vein, without signs of infiltration, in segment VIII on non-contrast scans, with rim-enhancement in the arterial phase (due to mass effect on the surrounding liver parenchyma) with the same attenuation as liver parenchyma during the delayed phase.

Liver enzymes and bilirubin values were within normal range. The serum tumor marker levels (CEA, CA 19-9 and AFP) were not elevated. The patient was negative for human immunodeficiency virus (HIV), hepatitis B and C (HBV, HCV) and Ebstein-Barr virus (EBV).

The patient underwent 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) positron emission computed tomography (18F-FDG PET-CT) for further functional characterization of the detected lesions and for staging of the disease. The exam revealed elevated 18F-FDG uptake only in liver segment VIII without pathological elevation in other organs (Figure 1). On esophagogastroduodenoscopy atrophic gastritis was present. Colonoscopy detected
anorectal polyps and enlarged hemorrhoidal nodes. A barium enema study revealed diverticulosis of the descendent and sigmoid colon. Extrahepatic disease was not detected.

The multidisciplinary tumor board opted for surgery and atypical resection of liver segments VII and VIII was performed. Lymphatic nodes in the hepatoduodenal ligament were dissected for frozen section analysis and proved to be benign.

Pathohistological examination of resected tumor revealed hepatic tissue with large nodular, tumorous, lymphoid infiltrates and numerous confluent necrotic fields, without tumor cells on the resection margin. Immunohistochemical staining showed that 90% of tumor cells had positive reaction for CD 20, CD79a, bcl 6, MUM 1 and Ki 67. These histological and immunohistochemical findings demonstrated liver infiltration with DBLCL (Figure 2).

Three weeks after the hospital discharge, the patient was presented with abdominal pain, nausea, vomiting and was promptly readmitted. Routine blood and biochemistry examination revealed elevated inflammatory markers and abdominal CT demonstrated pleural effusion, 150x97x103mm fluid collection in the right subphrenic space with a mean attenuation value of 22 HU and viscous fluid collection in the VI segment of the right liver lobe, containing gas inclusions, 95x57x110mm in diameter (Figure 3).

The patient was referred to the interventional radiology department for percutaneous drainage of the fluid collection at the liver resection site. Ultrasound guided initial puncture of the right subphrenic fluid collection was performed and specimen of viscous yellow fluid was sent for microbiological analysis followed by the placement of 10.2 Fr percutaneous drainage catheter in collection. Enterobacter spp. were isolated from the specimen and antibiotic therapy was initiated according to the antibiogram. Control CT scan of the abdomen revealed resolution of the subphrenic collection around the tip of the pigtail.
catheter. On follow-up ultrasound examination no fluid collection was detected and the patient was referred to the department of hematology for further treatment.

Bone marrow biopsy did not reveal lymphoma infiltration. Complete blood test excluded leukemic cells in the peripheral blood. Due to reduced left ventricular function (EF 55%) the lymphoma board decided to treat the patient with a R-miniCHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) low-dose chemotherapy protocol. She was given eight cycles of R-miniCHOP at 3-week intervals. During the course of chemotherapy, the patient occasionally complained of tingling in her hands and feet so vincristine was replaced with velban from sixth cycle to the end of treatment.

During three years follow-up the patient showed no symptoms or signs of recurrent disease (Figure 4).

**DISCUSSION**

Primary hepatic lymphoma (PHL) is an extra-nodal lymphoma of the liver without involvement of any other organ (lymph node, spleen, etc.) [4].

The most common presenting symptom in PHL is abdominal pain, occurring in more than 40% of patients. The B-symptoms of fever and weight loss occur in about one-third of the patients. Jaundice is seen in less than 20% of patients [5]. Our patient’s clinical presentation includes abdominal pain, nausea, weight loss, fatigue and were consistent with that of primary hepatic NHL.

Preexisting liver disease, such as chronic liver cirrhosis secondary to hepatitis B virus, hepatitis C virus, or hemochromatosis, is present in less than 9% of the patients [6]. In rare circumstances, progressive hepatitis and acute hepatic failure with rapid progression and poor prognosis may occur [7, 8].
The presented patient was diagnosed with NHL by pathohistological examination of the resected tumor. The pathological type was DLBCL. The involvement of other sites was excluded by lymph node examination, radiologic examinations (ultrasound, CT, PET CT, barium enema) and endoscopic examination (esophagastroduodenoscopy, colonoscopy).

Most PHL patients show a two to three-fold increase in ALT and AST levels, with an increase in bilirubin and HDL levels. However, AFP and CEA levels are usually normal, in contrast to those in primary liver cancer and liver metastasis [3]. The presented patient had normal liver enzyme and bilirubin values. Tumor markers (CEA, CA19-9, AFP) were not elevated.

The exact incidence and prevalence of PHL is not known. PHL is rare and comprises 0.4% of all cases of extra nodal NHL and 0.016% of all cases of NHL [2]. The male-to-female ratio is 1.9:1 [9]. The patient in this report was a 72-year-old female, although PHL is more common in males of around 50 years old.

Although primary hepatic lymphoma is rare, persistent inflammatory processes associated with HCV infection or autoimmune disease may play independent roles in the lymphomagenesis of hepatic B cells [10]. The presented patient was negative for HIV, AIDS, HBV, HCV and EBV and did not have any autoimmune disease.

There are three radiological presentations of PHL: 1) a solitary lesion, 2) multiple lesions within the liver and 3) diffuse hepatic infiltration. The most common presentation is a solitary lesion. The initial radiologic test is usually an ultrasound that demonstrates large, solitary hypoechoic lesion or multiple hypoechoic lesions resembling metastasis [11]. On CT scans, PHL lesions appear as hypoattenuating lesions and may have a central area of low intensity indicating necrosis. Following the administration of intravenous contrast, 50% of PHL lesions do not enhance, 33% show patchy enhancement, and 16% show a ring of enhancement [11]. CT scan of this patient revealed a hypoattenuating lesion in liver segment
VIII on non-enhanced scans, with rim-enhancement in the arterial phase, conceding with 16% ring enhancement as described in literature.

Due to the rarity of this disease entity and its nonspecific clinical presentation and laboratory and radiologic features, a definite clinical diagnosis of PHL is difficult. PHL may be confused with hepatitis, primary hepatic tumors, hepatic metastases from gastrointestinal carcinoma, and systemic lymphoma with secondary hepatic involvement [12].

Percutaneous liver biopsy is the most valuable tool for diagnosis of PHL. The transjugular approach is an alternative when a discrete mass is not visible on imaging for percutaneous liver biopsy [13]. A liver biopsy was not done because the liver lesion appeared malignant on radiological assessment and in order to avoid the risk of tumor seeding in resectable patient. Similar scenarios are described in the literature where patients, not correctly diagnosed as PHL, were operated for other diagnosis.

Treatment options for PHL include surgery, chemotherapy, radiation or combinations of these modalities.

It has been suggested that, for low-volume localized PHL, surgical resection, alone or in combination with chemotherapy, might be a treatment of choice. Lei described 10 patients treated with curative intent surgery who had a median survival of 22 months, ranging from 1.5 to 120 months [6]. Avlonitsi, in a large review of the literature, showed similar results that patients treated by surgery and followed by chemotherapy have better survival rates, with median survival of 15.3 months (range: 0-123.6 months) [5]. The current indications for surgery, based on the available data from the literature, include localised disease that can be completely resected [5].

R-CHOP chemotherapy regimen is the standard treatment for patients with DLBCL. There are reported cases of complete response to R-CHOP alone in patients with PHL-
DLBCL [14, 15]. Whether systemic chemotherapy alone will give results comparable to surgery in resectable cases is currently unclear [16].

In conclusion, PHL is a rare disease and can be misdiagnosed as another more frequent primary liver tumor due to its non-specific clinical presentation, laboratory and imaging findings and therefore should be considered in the differential diagnosis of a hepatic lesion. Pathohistological analysis is essential for definite diagnosis, determining PHL subtype and the extent of involvement of surrounding tissue. There is no consensus on the optimal treatment for PHL and the prognosis is variable. All complications during treatment should be diagnosed on time and properly managed. Further prospective studies are mandatory for providing treatment guidelines.

Conflict of interest: None declared.
REFERENCES

1. Padhan RK, Das P, Shalimar. Primary hepatic lymphoma. Trop Gastroenterol. 2015; 36:14-20. PMID: 26591949 DOI: 10.7869/tg.239

2. Loddenkemper C, Longerich T. Lymphoma of the liver. In: Cavalli F, Stein H, Zucca E, eds. Extranodal Lymphomas, Pathology and Management. Abingdon, UK: CRC Press; 2008. pp 277-88.

3. Liu Y, Jiang J, Wu Q, Zhang Q, Xu Y, Qu Z, Ma G, Wang X, et al. A Case of Primary Hepatic Lymphoma and Related Literature Review. Case Reports Hepatol. 2016; 2016:6764121. PMID: 27403354 DOI: 10.1155/2016/6764121

4. Agmon-Levin N, Berger I, Shtalrid M, Schlanger H, Shhoeger ZM. Primary hepatic lymphoma: a case report and review of the literature. Age Ageing. 2004; 33:637-40. PMID: 15381504 DOI: 10.1093/ageing/afh197

5. Avlonitis VS, Linos D. Primary hepatic lymphoma: a review. Eur J Surg. 1999; 165:725-9. PMID: 10494635 DOI: 10.1080/1024159950189474

6. Lei KI. Primary non-Hodgkin's lymphoma of the liver. Leuk Lymphoma. 1998; 29:293-9. PMID: 9684927 DOI: 10.3109/10428199809068566

7. El Nouwar R, El Murr T. Primary Hepatic Diffuse Large B-cell Lymphoma Mimicking Acute Fulminant Hepatitis: A Case Report and Review of the Literature. Eur J Case Rep Intern Med. 2018;5(6):000878. PMID: 30756046 DOI:10.12890/2018_000878

8. Haider FS, Smith R, Khan S. Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report. J Med Case Rep. 2008; 2:279. PMID: 18710584 DOI: 10.1186/1752-1947-2-279

9. Ugurluer G, Miller RC, Li Y, Thariat J, Ghadjar P, Schick U, Oezsahin M. Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study. Rare Tumors.2016;8:6502. PMID: 22395482 DOI: 10.1007/s00428-012-1199-x

10. Ippolito D, Porta M, Maino C, et al. Diagnostic approach in hepatic lymphoma: radiological imaging findings and literature review. J Cancer Res Clin Oncol. 2020;146(6):1545-1558. PMID: 32296934 DOI:10.1007/s00432-020-03205-x

11. Bouliaris K, Christodoulidis G, Koukoulis G, et al. Primary hepatic lymphoma treated with liver resection and chemotherapy. Case Rep Surg. 2014;2014:749509. PMID: 25165610 DOI:10.1155/2014/749509

12. Zentar A, Tarchouli M, Elkaoui H, Belhamidi MS, Ratbi MB, Bouchentouf SM, Ali AA, Boumaim A, Sair K. Primary hepatic lymphoma. J Gastrointest Cancer. 2014;45:380-2. PMID: 23686662 DOI: 10.1007/s12029-013-9505-7

13. Zafar MS, Aggarwal S, Bhalla S. Complete response to chemotherapy in primary hepatic lymphoma. J Cancer Res Ther. 2012;8:114-6. PMID: 22531527 DOI: 10.4103/0973-1482.95187

14. Kang NW, Kuo YH, Wu HC, Chen WY, Huang CT, Chuang SS, Feng YH. Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy. Journal of Cancer Research and Practice. 2017;4(4):139-42. DOI: 10.1016/j.jcrrp.2017.07.004

15. Park JI, Jung BH. Primary hepatic lymphoma treated with liver resection followed by chemotherapy: a case report. Ann Hepatobiliary Pancreat Surg. 2017;21:163-167. PMID: 28990004 DOI: 10.14701/ahbps.2017.21.3.163
Figure 1. Contrast-enhanced abdominal computed tomography and F-18 FDG PET scan in coronal plane: (A) arterial phase showing a hypoattenuating, slightly lobulated, lesion in segment VIII with peripheral rim-enhancement; (B) hypodense lesion during portal phase; (C) same attenuation as liver parenchyma during the delayed phase; (D) hypermetabolic mass lesion in the liver.
Figure 2. Microscopic findings of the liver confirming non-Hodgkin’s diffuse large B-cell lymphoma. (A) Diffuse proliferation of lymphoid cells (H&E, ×200); (B) positive for CD20; (C) positive for bcl 6; (D) positive for Ki 67.
Figure 3. Postoperative computed tomography scan in coronal plane demonstrating pleural effusion, fluid collection in the right subphrenic space and viscous fluid collection in the VI segment of the liver.
Figure 4. Computed tomography scan after three years follow-up in axial and coronal plane demonstrating no signs of recurrent disease.